CN115666616A - 用于病毒感染的化合物 - Google Patents

用于病毒感染的化合物 Download PDF

Info

Publication number
CN115666616A
CN115666616A CN202180018734.0A CN202180018734A CN115666616A CN 115666616 A CN115666616 A CN 115666616A CN 202180018734 A CN202180018734 A CN 202180018734A CN 115666616 A CN115666616 A CN 115666616A
Authority
CN
China
Prior art keywords
day
compound
substituted
unsubstituted
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180018734.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·阿维莱斯·马林
A·洛萨达·冈萨雷斯
J·M·费南德斯·索萨-法罗
S·夫迪奥·穆尼奥斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN115666616A publication Critical patent/CN115666616A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180018734.0A 2020-03-02 2021-03-02 用于病毒感染的化合物 Pending CN115666616A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382152.5 2020-03-02
EP20382192 2020-03-13
EP20382192.1 2020-03-13
EP20382266.3 2020-04-02
EP20382266 2020-04-02
EP20382339.8 2020-04-27
EP20382339 2020-04-27
EP20382816 2020-09-16
EP20382815.7 2020-09-16
EP20382816.5 2020-09-16
EP20382815 2020-09-16
EP21382059 2021-01-25
EP21382059.0 2021-01-25
PCT/EP2021/055147 WO2021175831A2 (en) 2020-03-02 2021-03-02 Compounds for use in viral infections

Publications (1)

Publication Number Publication Date
CN115666616A true CN115666616A (zh) 2023-01-31

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180018734.0A Pending CN115666616A (zh) 2020-03-02 2021-03-02 用于病毒感染的化合物
CN202180018363.6A Pending CN115461067A (zh) 2020-03-02 2021-03-02 用于炎症的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180018363.6A Pending CN115461067A (zh) 2020-03-02 2021-03-02 用于炎症的化合物

Country Status (17)

Country Link
US (2) US12630589B2 (cg-RX-API-DMAC7.html)
EP (2) EP4114433A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023517536A (cg-RX-API-DMAC7.html)
KR (2) KR20220151643A (cg-RX-API-DMAC7.html)
CN (2) CN115666616A (cg-RX-API-DMAC7.html)
AU (2) AU2021232535A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016604A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169540A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002396A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014031A2 (cg-RX-API-DMAC7.html)
IL (2) IL296069A (cg-RX-API-DMAC7.html)
MX (2) MX2022010921A (cg-RX-API-DMAC7.html)
PE (2) PE20230412A1 (cg-RX-API-DMAC7.html)
PY (2) PY2117301A (cg-RX-API-DMAC7.html)
TW (2) TW202144381A (cg-RX-API-DMAC7.html)
UY (2) UY39110A (cg-RX-API-DMAC7.html)
WO (2) WO2021175831A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114436A1 (en) * 2020-03-02 2023-01-11 Pharma Mar S.A. Compounds for use in the treatment of coronavirus infection
CN115666616A (zh) 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物
IL296067A (en) * 2020-03-02 2022-11-01 Pharma Mar Sa Pld for use in combination in the treatment of coronavirus
WO2024165764A1 (en) * 2023-02-10 2024-08-15 Pharma Mar, S.A. Plitidepsin for use in the treatment of non-integrated dna viral infections
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834586A (en) * 1989-09-29 1998-11-10 Pharma Mar, S.A. Dehydrodidemnin B
CN101389347A (zh) * 2006-02-28 2009-03-18 法马马有限公司 提高的抗肿瘤治疗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
BR9909668A (pt) * 1998-04-14 2000-12-19 Jomaa Hassan Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
ES2272462T3 (es) 2000-04-07 2007-05-01 The Trustees Of The University Of Pennsylvania Analogos de tamadarina y didemnina y procedimiento de fabricacion y uso.
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP4623931B2 (ja) * 2000-12-07 2011-02-02 エンセラデュス、ファーマシューティカルズ、ベスローテン、フェンノートシャップ 炎症性疾患の治療用組成物
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
AU2004224418A1 (en) 2003-03-21 2004-10-07 Madeleine M. Joullie Tamandarin analogs and fragments thereof and methods of making and using
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds
JP5814933B2 (ja) * 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
US20120040033A1 (en) * 2010-08-10 2012-02-16 Ernest Timothy Armstrong Anti-infective mangrove extract against viruses, bacteria and fungi
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
JP2017526728A (ja) * 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
US11771739B2 (en) * 2017-06-16 2023-10-03 Vanderbilt University Methods and compositions for treating microbial inflammation
CN115666616A (zh) * 2020-03-02 2023-01-31 法马马有限公司 用于病毒感染的化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834586A (en) * 1989-09-29 1998-11-10 Pharma Mar, S.A. Dehydrodidemnin B
CN101389347A (zh) * 2006-02-28 2009-03-18 法马马有限公司 提高的抗肿瘤治疗

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. ARTURO LEIS等: "Lazarus Effect of High Dose Corticosteroids in a Patient With West Nile Virus Encephalitis: A Coincidence or a Clue?"", FRONTIERS IN MEDICINE, vol. 6, 25 April 2019 (2019-04-25), pages 1 - 4 *
ALEJANDRO LOSADA等: "Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin", SCIENTIFIC REPORTS, vol. 6, 7 October 2016 (2016-10-07) *
K L RINEHART JR等: "Didemnins: antiviral and antitumor depsipeptides from a caribbean tunicate", SCIENCE, vol. 212, no. 4497, 22 May 1981 (1981-05-22), pages 2 *
WILLIAM G. DAVIS等: "Interaction between the Cellular Protein eEF1A and the 3′-Terminal Stem-Loop of West Nile Virus Genomic RNA Facilitates Viral Minus-Strand RNA Synthesis", OURNAL OF VIROLOGY, vol. 81, no. 18, 11 July 2007 (2007-07-11) *
YUE-NAN NI等: "The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis", CRITICAL CARE, vol. 23, 27 March 2019 (2019-03-27), pages 99 *

Also Published As

Publication number Publication date
CO2022014093A2 (es) 2022-11-18
KR20220151643A (ko) 2022-11-15
PE20230606A1 (es) 2023-04-10
BR112022016675A2 (pt) 2022-10-11
JP2023517535A (ja) 2023-04-26
CN115461067A (zh) 2022-12-09
PY2117301A (es) 2022-08-09
PE20230412A1 (es) 2023-03-07
UY39110A (es) 2021-09-30
US20230295236A1 (en) 2023-09-21
WO2021175831A2 (en) 2021-09-10
US20230159594A1 (en) 2023-05-25
CO2022014031A2 (es) 2022-10-21
EP4114433A2 (en) 2023-01-11
AU2021232535A1 (en) 2022-10-06
WO2021175831A3 (en) 2021-10-14
UY39109A (es) 2021-09-30
BR112022016604A2 (pt) 2022-10-11
IL296069A (en) 2022-11-01
MX2022010921A (es) 2022-09-29
CA3169544A1 (en) 2021-09-10
US12630589B2 (en) 2026-05-19
EP4114435A1 (en) 2023-01-11
TWI908772B (zh) 2025-12-21
WO2021175857A1 (en) 2021-09-10
KR20220150350A (ko) 2022-11-10
IL296068A (en) 2022-11-01
TW202146038A (zh) 2021-12-16
CL2022002396A1 (es) 2023-06-30
JP2023517536A (ja) 2023-04-26
CL2022002395A1 (es) 2023-06-30
AU2021231197A1 (en) 2022-10-06
MX2022010926A (es) 2022-09-29
TW202144381A (zh) 2021-12-01
PY2117308A (es) 2022-08-09
CA3169540A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
TWI908772B (zh) 用於病毒感染之化合物
EP3349751A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
JP7433331B2 (ja) 特発性肺線維症を治療するための組成物及び方法
CN115243703A (zh) 用于组合治疗冠状病毒的pld
CN115666615A (zh) 用于治疗冠状病毒感染的化合物
CN103724334A (zh) 新的抗变态反应的苯并环庚并噻吩类化合物
JP2023517537A (ja) 自己免疫状態に使用するための化合物
EA050127B1 (ru) Соединения для применения при аутоиммунных состояниях
WO2024165764A1 (en) Plitidepsin for use in the treatment of non-integrated dna viral infections
KR20250002212A (ko) 인플루엔자 및 폭스바이러스 바이러스 감염을 치료하는 방법
EA050436B1 (ru) Соединения для применения при воспалительных состояниях
KR20220043047A (ko) 스핑고신-1-인산 수용체 효능제의 용도
CN119326767A (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
KR20090127072A (ko) 신규 디아릴 헵타노이드계 화합물 및 그 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination